FDAsafety guidance72% confidence
Guidance Recap Podcast | Assessing the Effects of Food on Drugs in INDs and NDAs – Clinical Pharmacology Considerations
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Biogen.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Neurology · Friedrich's Ataxia
- Sub-indication
- General
Related signal: Biogen initiates observational study on omaveloxolone's effects during pregnancy and breastfeeding